Homozygosity for the G2M*n allele and the GM*b;f;n haplotype confers resistance to invasive infection in C2D
| G2M Allotypeb . | G2M(n,n) . | G2M(n,n−) . | . | . | G2M(n−,n−) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GM Haplotype . | *b;f;n/b;f;n . | *b;f;n/g;a;n− . | *b;f;n/*b;f;n− . | *n/n− . | *b;f;n−/g;a;n− . | *g;a;n−/g;a;n− . | *b;f;n −/*b;f;n− . | ||||
| Group 1 (n = 12) | 7c | 2d | 0d | 1e | 0 | 1 | 1 | ||||
| Group 2 (n = 7) | 0 | 6 | 0 | 1 | 0 | 0 | |||||
| Group 3 (n = 12) | 0 | 4 | 5 | 3 | 0 | 0 | |||||
| Group 4 (n = 13) | 2 | 4 | 2 | 4 | 0 | 1 | |||||
| Total (n = 44) | 20.9% | 37.2% | 16.3% | 18.6% | 2.3% | 4.7% | |||||
| Controls (n = 430)f | 19.3% | 27.2% | 17.4% | 17.7% | 9.8% | 6.7% | |||||
| G2M Allotypeb . | G2M(n,n) . | G2M(n,n−) . | . | . | G2M(n−,n−) . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GM Haplotype . | *b;f;n/b;f;n . | *b;f;n/g;a;n− . | *b;f;n/*b;f;n− . | *n/n− . | *b;f;n−/g;a;n− . | *g;a;n−/g;a;n− . | *b;f;n −/*b;f;n− . | ||||
| Group 1 (n = 12) | 7c | 2d | 0d | 1e | 0 | 1 | 1 | ||||
| Group 2 (n = 7) | 0 | 6 | 0 | 1 | 0 | 0 | |||||
| Group 3 (n = 12) | 0 | 4 | 5 | 3 | 0 | 0 | |||||
| Group 4 (n = 13) | 2 | 4 | 2 | 4 | 0 | 1 | |||||
| Total (n = 44) | 20.9% | 37.2% | 16.3% | 18.6% | 2.3% | 4.7% | |||||
| Controls (n = 430)f | 19.3% | 27.2% | 17.4% | 17.7% | 9.8% | 6.7% | |||||
The G2M(n) and G2M(n−) allotypes and the associated GM haplotypes are given in the C2D patients, who were divided into groups according to the severity of the infections (see Table I).
In 40 patients, confirmatory investigation of G2Mn and G2Mn− was performed by DNA analysis.
p < 0.001 (Fisher’s exact test) for the homozygous presence of G2M(n) in group 1 compared with groups 2–4.
As compared with the GMb;f;n− haplotype, the increased prevalence of the GMg;a;n− haplotype among heterozygous patients with noninvasive infections was not statistically significant (p = 0.15, Mann-Whitney U test).
One patient could only be analyzed for G2M(n) due to lack of serum.
The distribution of GM haplotypes in the C2D cohort did not differ (p = 0.72, CHI2 test) from that found in a previously described control population (22 ).